The COVID-19 pandemics and the relevance of biosafety facilities for metagenomics surveillance, structured disease prevention and control

作     者：Thiago Moreno L.Souza Carlos Medicis Morel Thiago Moreno L.Souza;Carlos Medicis Morel

作者机构：National Institute of Science and Technology for Innovation on Diseases of Neglected Populations(INCT-IDPN)Centre for Technological Development in Health(CDTS)Oswaldo Cruz Foundation(Fiocruz)Avenida Brasil 4365ManguinhosRio de JaneiroRJ 21045-900Brazil 

出 版 物：《Biosafety and Health》 (生物安全与健康（英文）)

年 卷 期：2021年第3卷第1期

页      面：1-3页

核心收录：

学科分类：12[管理学] 1204[管理学-公共管理] 120402[管理学-社会医学与卫生事业管理(可授管理学、医学学位)] 1004[医学-公共卫生与预防医学(可授医学、理学学位)] 10[医学] 

基　　金：supported by CNPq(ConselhoNacional deDesenvolvimento Cientifico e Tecnologico),FAPERJ(Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro)through grants received by TMLS Funding was also provided by CNPq,CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior)and FAPERJ through the National Institutes of Science and Technology Program(INCT)to CMM(INCT-IDPN) Thanks are due to Oswaldo Cruz Foundation/FIOCRUZ under the auspicious of Inova program(B3-Bovespa funding) 

主　　题：SARS-CoV-2 COVID-19 Biosafety facilities Innovative Developing Countries(IDCs) Metagenomics surveillance 

摘      要：The coronavirus disease 2019(COVID-19)pandemic represents an enormous challenge to all countries,regardless of their development *** manipulation of its etiologic agent SARS-CoV-2 requires a biosafety containment level 3 laboratories(BSL-3)to understand virus biology and in vivo pathogenesis as well as the translation of new knowledge into the preclinical development of vaccines and *** such,BSL-3 facilities should be considered an integral part of any public health response to emerging infectious disease prevention,control and *** from BSL-2,BSL-3 units vary considerably along the range from industrialized to the least developed *** Developing Countries(IDCs)such as Brazil,which excelled at controlling the 2015-2017 Zika epidemic,had to face a serious flaw in its disease control and prevention structure:the scarcity and uneven geographic distribution of its BSL-3 facilities,including those for preclinical animal experimentation.